Company / EPS (Diluted)
NewAmsterdam Pharma Co N.V. EPS (Diluted) History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$1.72
FY2025
5-year range
-$3.81 / -$1.19
FY2021-FY2025
Trend
+32.8%
vs FY2024
Sector context
#122 of 203
Health Care
What the data says
At $-1.72, NewAmsterdam Pharma Co N.V.'s eps (diluted) ranks #122 of 203 in the Health Care sector. EPS (Diluted) returned to growth in FY2025 after 2 years of decline, reaching $-1.72.
Based on SEC 10-K filings.
-1.72 in FY2025.
Improved from $-2.15 to $-1.72 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#122 of 203 in Health CareTop 60% of 203This company -$1.72 Sector average -$0.45
▼
-283.5% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 32.8% year-over-year.
- Ranks #122 out of 203 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2022.
- Lowest eps (diluted) in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.01 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.72 | +32.8% |
| FY2024 | -$2.56 | -19.1% |
| FY2023 | -$2.15 | -80.7% |
| FY2022 | -$1.19 | +68.8% |
| FY2021 | -$3.81 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026